NovoCure (NVCR) to Release Earnings on Thursday

NovoCure (NASDAQ:NVCR) will announce its earnings results before the market opens on Thursday, July 25th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $138.50 million during the quarter, compared to analysts’ expectations of $131.44 million. NovoCure had a negative return on equity of 50.35% and a negative net margin of 36.67%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) EPS. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NovoCure Price Performance

NovoCure stock opened at $18.77 on Wednesday. The firm has a market capitalization of $2.02 billion, a P/E ratio of -10.37 and a beta of 0.70. NovoCure has a 1 year low of $10.87 and a 1 year high of $41.51. The business has a 50-day moving average of $20.01 and a 200-day moving average of $16.47. The company has a current ratio of 6.26, a quick ratio of 5.99 and a debt-to-equity ratio of 1.59.

Analysts Set New Price Targets

Several equities analysts recently issued reports on NVCR shares. Piper Sandler reiterated an “overweight” rating and issued a $28.00 price objective (up from $25.00) on shares of NovoCure in a research report on Wednesday, April 10th. Wells Fargo & Company decreased their price objective on NovoCure from $49.00 to $42.00 and set an “overweight” rating for the company in a research report on Wednesday, April 3rd. HC Wainwright restated a “neutral” rating and issued a $22.00 target price on shares of NovoCure in a research note on Tuesday, June 4th. Wedbush restated an “outperform” rating and issued a $24.00 target price (up previously from $21.00) on shares of NovoCure in a research note on Monday, June 3rd. Finally, Evercore ISI boosted their target price on NovoCure from $14.50 to $20.00 and gave the company an “in-line” rating in a research note on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.88.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.